TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26235006

Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Problematic family functioning
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Larger household size
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Adverse neurological event(s) during therapy
Number of subjects: 160
Study: 24373344

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - 3 monthly injections of 1.25 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT) - 2 injections of 2 mg 2 months apart
Number of subjects: 86
Study: 23403997

Group type: EXPERIMENTAL
Intervention: Presence of plaque
Number of subjects: 0

Group type: COMPARATOR
Intervention: No plaque (Control group)
Number of subjects: 0
Study: 18786981

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Carboplatin (GC)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Cisplatin and Etoposide (PE)
Number of subjects: 241
Study: 17965485

Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel or ticlopidine (Group I, n=28)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel or ticlopidine plus cilostazol (Group II, n=31)
Number of subjects: 59
Study: 15039501

Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (disclosure writing)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control writing (writing about positive events)
Number of subjects: 48
Study: 11193233

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) oral suspension of 800 mg/d for 12 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 9777138

Group type: EXPERIMENTAL
Intervention: Hirulog and aspirin before streptokinase
Number of subjects: 17000

Group type: EXPERIMENTAL
Intervention: Hirudin with streptokinase
Number of subjects: 17000

Group type: EXPERIMENTAL
Intervention: Hirulog with streptokinase
Number of subjects: 17000

Group type: COMPARATOR
Intervention: Heparin with streptokinase
Number of subjects: 17000
Study: 8172139

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (no treatment or placebo)
Number of subjects: 5
Study: 2898499

Group type: EXPERIMENTAL
Intervention: Chlorhexidine scrub
Number of subjects: 2015

Group type: COMPARATOR
Intervention: Plain soap (Control)
Number of subjects: 2015

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2015
Study: 30522806

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 0.5–0.6 × 10^8 allogenic placenta-derived MSCs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 20
Study: 28152327

Group type: EXPERIMENTAL
Intervention: Therapist-implemented Project ImPACT (2 hours per week)
Number of subjects: 9
Study: 26353784

Group type: EXPERIMENTAL
Intervention: Truce program (7-week acceptance and commitment therapy)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 65
Study: 23410527

Group type: EXPERIMENTAL
Intervention: Aromatherapy inhalation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 13
Study: 21646292

Group type: EXPERIMENTAL
Intervention: Campaign advertisements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consumer adverts (control)
Number of subjects: 0
Study: 19142978

Group type: EXPERIMENTAL
Intervention: Prelox (combination of l-arginine aspartate and Pycnogenol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17519075

Group type: EXPERIMENTAL
Intervention: IL‐12/23 mAb (0.27, 0.675, 1.35, and 2.7 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IL‐12/23 mAb
Number of subjects: 21
Study: 16145426

Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study: 12359791

Group type: EXPERIMENTAL
Intervention: EMLA (applied for 60 minutes)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ELA-Max (applied for 30 minutes)
Number of subjects: 30
Study: 10606880

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH), 250 U/kg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH), 300 U/kg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dalteparin, 200 U/kg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Enoxaparin, 1.5 mg/kg once daily
Number of subjects: 12
Study: 7750288

Group type: EXPERIMENTAL
Intervention: High doses of vitamin C (gram quantities)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination oral contraceptive alone
Number of subjects: 0
Study: 2292897

Group type: EXPERIMENTAL
Intervention: Teolin 300 tablets (TT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Teotard 350 capsules (TC)
Number of subjects: 7
Study: 7016451

Group type: EXPERIMENTAL
Intervention: 800 mg tolmetin sodium daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: 500 mg naproxen daily
Number of subjects: 70
Study: 31180146

Group type: EXPERIMENTAL
Intervention: Haptic feedback device fitted to existing syringes
Number of subjects: 14
Study: 27896797

Group type: EXPERIMENTAL
Intervention: Step-up to Quit (SUTQ) intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard smoking cessation counseling (control)
Number of subjects: 101
Study: 25517106

Group type: EXPERIMENTAL
Intervention: 7.5% sucrose drink containing 6 g of l-citrulline
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 710 mL of watermelon juice (1.0 g citrulline)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 7.5% sucrose placebo drink
Number of subjects: 22
Study: 24315273

Group type: EXPERIMENTAL
Intervention: Familiar scent (vanillin) exposure during arterial puncture after familiarization with the scent for an average of 8.65 hours.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Non-familiarized scent exposure during arterial puncture.
Number of subjects: 135

Group type: COMPARATOR
Intervention: No scent exposure during arterial puncture.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Familiar scent (vanillin) exposure during arterial puncture.
Number of subjects: 135
Study: 21679291

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (single pre-prandial dose)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Insulin glargine (basal-only control)
Number of subjects: 106
Study: 19906123

Group type: EXPERIMENTAL
Intervention: Self-affirmation writing assignment
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control writing assignment
Number of subjects: 405
Study: 16904450

Group type: EXPERIMENTAL
Intervention: Periprostatic local anesthesia (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Caudal block (Group 2)
Number of subjects: 100
Study: 15012046

Group type: EXPERIMENTAL
Intervention: Exercise during dialysis (cycling ergometer sessions, twice weekly for 12 sessions)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 17
Study: 11708421

Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Prednisone (PR)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study: 9076247

Group type: EXPERIMENTAL
Intervention: Paired tone condition (MMF.P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single tone condition (MMF.S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paired tone condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single tone condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paired stimuli
Number of subjects: 0
Study: 8426028

Group type: EXPERIMENTAL
Intervention: Inpatient Geriatric Consultation Team (multidimensional geriatric assessment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 120
Study: 3149155

Group type: EXPERIMENTAL
Intervention: Atropine + Fentanyl
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atropine + Alfentanil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no atropine, no analgetic)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 90
Study: 29111077

Group type: EXPERIMENTAL
Intervention: Active tDCS (2.5 mA, 30 min, 20 sessions over 4 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sham tDCS (0.034 mA and two 60‐second current ramps up to 1 and 0.5 mA, 20 sessions over 4 weeks)
Number of subjects: 130
Study: 27225596

Group type: EXPERIMENTAL
Intervention: Regular entrée
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Higher protein entrée
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control (self-selected foods)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Intervention (portion-controlled prepackaged foods)
Number of subjects: 183
Study: 25783434

Group type: EXPERIMENTAL
Intervention: Online theory-based intervention to improve GFD adherence over six weeks
Number of subjects: 74
Study: 22395054

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline solution (control group)
Number of subjects: 45
Study: 21813912

Group type: EXPERIMENTAL
Intervention: NO(2) Platinum (12 g/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 24
Study: 19103500

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g bolus before skin incision and 400 mg/h during surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study: 16982564

Group type: EXPERIMENTAL
Intervention: Intravascular coil placement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Percutaneous intrathoracal placement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Percutaneous extrathoracal placement
Number of subjects: 20
Study: 15229419

Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 82

Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 82
Study: 11209950

Group type: EXPERIMENTAL
Intervention: Associative recognition test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Old item recognition test
Number of subjects: 0
Study: 9265991

Group type: EXPERIMENTAL
Intervention: Cetirizine treatment for allergic cough
Number of subjects: 20
Study: 8500308

Group type: EXPERIMENTAL
Intervention: New method of estimation for analyzing compliance in randomized trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intent-to-treat analysis
Number of subjects: 0
Study: 3404638

Group type: EXPERIMENTAL
Intervention: Adjusted-dose heparin (mean 13,200 +/- 2200 U per dose, APTT 1 1/2 times control)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fixed-dose heparin (5000 U subcutaneously twice daily)
Number of subjects: 75
Study: 30346496

Group type: COMPARATOR
Intervention: Standard PIL (e.g., 'Common, 1 in 10 people will be affected')
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Positively framed PIL (e.g., 'Uncommon, 90% of people will not be affected')
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard PIL
Number of subjects: 203
Study: 29284810

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 53
Study: 25785768

Group type: EXPERIMENTAL
Intervention: Silicone drain (SD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Polyvinyl chloride drain (PVCD)
Number of subjects: 200
Study: 24093853

Group type: EXPERIMENTAL
Intervention: Bleeding rates among women (8.2%)
Number of subjects: 10006

Group type: EXPERIMENTAL
Intervention: Bleeding and 30-day mortality association among men
Number of subjects: 10006

Group type: EXPERIMENTAL
Intervention: Bleeding and 30-day mortality association among women
Number of subjects: 10006

Group type: EXPERIMENTAL
Intervention: Landmark analysis of 120-hour survivors
Number of subjects: 10006
Study: 21167315

Group type: EXPERIMENTAL
Intervention: Fluoroscopy + AcuNav intracardiac ultrasound + NavX electroanatomic mapping
Number of subjects: 74

Group type: COMPARATOR
Intervention: Fluoroscopy only
Number of subjects: 74
Study: 18292676

Group type: EXPERIMENTAL
Intervention: Nitrous oxide with 30% oxygen
Number of subjects: 70

Group type: COMPARATOR
Intervention: Air with 30% oxygen
Number of subjects: 70
Study: 16539047

Group type: EXPERIMENTAL
Intervention: Higher density annulus of macular pigment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimodal distribution of macular pigment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maxwell's spot
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shape of the foveal depression
Number of subjects: 0
Study: 12760589

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg 8 hourly for two weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for two weeks
Number of subjects: 10
Study: 10857950

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (AHT) with enalapril or metoprolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: No antihypertensive treatment (AHT)
Number of subjects: 30
Study: 8904862

Group type: EXPERIMENTAL
Intervention: No missed opportunities intervention (changing practice policy to screen and vaccinate eligible children at all visits)
Number of subjects: 1988

Group type: EXPERIMENTAL
Intervention: Immunization reminder cards attached to medical charts
Number of subjects: 1988

Group type: EXPERIMENTAL
Intervention: No missed opportunities intervention
Number of subjects: 1988

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1988
Study: 2053757

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 1 or 2 g of oxacillin before surgery, followed by four days of oral oxacillin (3 g per day).
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group without the use of prophylactic antibiotics.
Number of subjects: 209
Study: 7049344

Group type: EXPERIMENTAL
Intervention: Intrathecal therapy with methotrexate, hydrocortisone, and cytosine arabinoside plus cranial radiation (2400 rad over 2 1/2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrathecal therapy with methotrexate, hydrocortisone, and cytosine arabinoside without cranial radiation
Number of subjects: 0
Study: 30200774

Group type: EXPERIMENTAL
Intervention: Trauma-informed care (TIC) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed cohort (control)
Number of subjects: 0
Study: 27440803

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 132

Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 132
Study: 26469916

Group type: EXPERIMENTAL
Intervention: Collection of wound exudate during dressing changes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard therapy without collection of wound exudate
Number of subjects: 18
Study: 23950186

Group type: EXPERIMENTAL
Intervention: Internal Family Systems (IFS) intervention for 9 months
Number of subjects: 79

Group type: COMPARATOR
Intervention: Education (control) group receiving mailed materials on RA symptoms and management
Number of subjects: 79
Study: 21207054

Group type: EXPERIMENTAL
Intervention: CRE + CAF (0.3 g kg(‐1) day(‐1) of creatine for 5 days and followed by 6 mg kg(‐1) of caffeine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CRE + PLA (0.3 g kg(‐1) day(‐1) of creatine for 5 days then followed by 6 mg kg(‐1) of placebo)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (no ergogenic aids)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CRE + CAF
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CRE + PLA
Number of subjects: 12
Study: 18838101

Group type: EXPERIMENTAL
Intervention: Initial control over aversive stimulation followed by loss of control and restitution of control
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Uncontrollable stress
Number of subjects: 66

Group type: COMPARATOR
Intervention: No prior control
Number of subjects: 66
Study: 17502449

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 301

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 301
Study: 15467309

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) at a dose of 2 microg/kg intranasally
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 15
Study: 11208820

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation with cisplatin, fluorouracil, and vinblastine; cisplatin 20 mg/m2/d on days 1-5 and 17-21, fluorouracil 300 mg/m2/d on days 1-21, vinblastine 1 mg/m2/d on days 1-4 and 17-20, radiotherapy 1.5-Gy fractions twice daily for 21 days to a total dose of 45 Gy.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery alone (arm I).
Number of subjects: 100
Study: 9577425

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite coated bicylindrical pins
Number of subjects: 21

Group type: COMPARATOR
Intervention: Uncoated bicylindrical pins
Number of subjects: 21

Group type: COMPARATOR
Intervention: Uncoated pins
Number of subjects: 21
Study: 8148868

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 14
Study: 3275909

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 35 micrograms plus ethynodiol diacetate 1 mg
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 30 micrograms plus levonorgestrel 0.15 mg
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 35 micrograms plus norethindrone 1 mg
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 35 micrograms plus norethindrone 0.5 and 1 mg (biphasic)
Number of subjects: 266
Study: 31492485

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DX)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31116358

Group type: EXPERIMENTAL
Intervention: Targeting mean arterial pressure using cerebral autoregulation monitoring during cardiopulmonary bypass (CPB)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual care (mean arterial pressure targets determined according to institutional practice)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Targeting mean arterial pressure using cerebral autoregulation monitoring during CPB
Number of subjects: 199
Study: 29176540

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not taking OCP)
Number of subjects: 24
Study: 24711000

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 100mg/kg/day as intermittent intravenous infusion from day -6 to day +15
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 80
Study: 23902627

Group type: EXPERIMENTAL
Intervention: Postpartum support video and/or hotline service
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal work
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Planned pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intention to breastfeed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Source of maternal emotional support
Number of subjects: 0
Study: 21369770

Group type: EXPERIMENTAL
Intervention: Adequate literacy
Number of subjects: 605

Group type: COMPARATOR
Intervention: Low literacy
Number of subjects: 605
Study: 19185807

Group type: EXPERIMENTAL
Intervention: California Hospital Safety and Security Act (post-enactment period 1996-2001)
Number of subjects: 116

Group type: COMPARATOR
Intervention: New Jersey hospitals (control group)
Number of subjects: 116
Study: 16995478

Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative IL-2 administration (19 patients)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Surgery alone (control group, 20 patients)
Number of subjects: 39
Study: 12826247

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 0
Study: 10964639

Group type: EXPERIMENTAL
Intervention: Sociobehavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 0
Study: 8636768

Group type: COMPARATOR
Intervention: Dexamethasone, cisplatin, and cytarabine (DHAP)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (carmustine, etoposide, cytarabine, and cyclophosphamide [BEAC]) followed by autologous bone marrow transplantation (ABMT)
Number of subjects: 49
Study: 1619995

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg bolus followed by 0.04 mg/kg/h infusion)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study: 6142030

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 7
Study: 30955478

Group type: EXPERIMENTAL
Intervention: Educational text messages about osteoporosis (daily for one month)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Educational text messages on frequently occurring cancers in women (control group)
Number of subjects: 121
Study: 29461966

Group type: EXPERIMENTAL
Intervention: 30 minutes at 60% V . O2peak (30MI)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 30 minutes at 80% V . O2peak (30HI)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 120 minutes at 60% V . O2peak (120MI)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Rested (CON)
Number of subjects: 64
Study: 27206514

Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 24305799

Group type: EXPERIMENTAL
Intervention: 0.4% permethrin-impregnated underwear
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo underwear
Number of subjects: 73
Study: 22166068

Group type: EXPERIMENTAL
Intervention: Epidural analgesia during labor (Group A)
Number of subjects: 128

Group type: COMPARATOR
Intervention: No analgesia (Group B)
Number of subjects: 128
Study: 20375102

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe renal dysfunction (C(cr) < 60)
Number of subjects: 1975

Group type: COMPARATOR
Intervention: Normal renal function
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Adjusted for history of hypertension
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Adjusted for hypercholesterolemia
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Adjusted for diabetes
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Adjusted for smoking habits
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Adjusted for physical activity status
Number of subjects: 1975